Abstract
A 26-kDa trypsin inhibitor with an N-terminal sequence resembling storage proteins was purified from moth beans (Phaseolus acutifolius). It dose-dependently inhibited trypsin with an IC50 value of about 0.38 μM. It inhibited [methyl-3H] thymidine incorporation by lymphoma MBL2 cells with an IC50 value of 20 μM.
Keywords: antiproliferative, lymphoma cells, moth bean, purification, storage protein, trypsin inhibitor
Protein & Peptide Letters
Title: A Storage Protein-Like Trypsin Inhibitor from the Moth Bean (Phaseolus acutifolius) with Antiproliferative Activity Toward Lymphoma Cells
Volume: 17 Issue: 6
Author(s): D.Z. Ma, J. Sun, G.Q. Zhang, H.X. Wang and T.B. Ng
Affiliation:
Keywords: antiproliferative, lymphoma cells, moth bean, purification, storage protein, trypsin inhibitor
Abstract: A 26-kDa trypsin inhibitor with an N-terminal sequence resembling storage proteins was purified from moth beans (Phaseolus acutifolius). It dose-dependently inhibited trypsin with an IC50 value of about 0.38 μM. It inhibited [methyl-3H] thymidine incorporation by lymphoma MBL2 cells with an IC50 value of 20 μM.
Export Options
About this article
Cite this article as:
Ma D.Z., Sun J., Zhang G.Q., Wang H.X. and Ng T.B., A Storage Protein-Like Trypsin Inhibitor from the Moth Bean (Phaseolus acutifolius) with Antiproliferative Activity Toward Lymphoma Cells, Protein & Peptide Letters 2010; 17 (6) . https://dx.doi.org/10.2174/092986610791190408
DOI https://dx.doi.org/10.2174/092986610791190408 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Optimizing Target Selection and Development Strategy in Cancer Treatment; The Next Wave
Current Medicinal Chemistry - Anti-Cancer Agents SYNTHESIS AND APPLICATIONS OF Fe3O4/SiO2 CORE-SHELL MATERIALS
Current Pharmaceutical Design Review: The JAK/STAT Protein Activation – Role in Cancer Development and Targeted Therapy
Current Signal Transduction Therapy Pathophysiological and Clinical Aspects of Iron Chelation Therapy in MDS
Current Pharmaceutical Design Patent Selections
Recent Patents on Nanomedicine Molecular Targets from VHL Studies into the Oxygen-Sensing Pathway
Current Cancer Drug Targets Two Promising Anti-Cancer Compounds, 2-Hydroxycinnaldehyde and 2- Benzoyloxycinnamaldehyde: Where do we stand?
Combinatorial Chemistry & High Throughput Screening Gene Therapy of Cancer with Interleukin-12
Current Pharmaceutical Design Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Targeting the G2/M Transition for Antitumor Therapy
Letters in Drug Design & Discovery Use of E. coli Purine Nucleoside Phosphorylase in the Treatment of Solid Tumors
Current Pharmaceutical Design Apoptosis-Inducing Effects of Amaryllidaceae Alkaloids
Current Medicinal Chemistry Destroying RNA as a Therapeutic Approach
Current Medicinal Chemistry The Smart Targeting of Nanoparticles
Current Pharmaceutical Design Prospects for Clinical Introduction of Nitroimidazole Antibiotics for the Treatment of Tuberculosis
Current Pharmaceutical Design Helper T Cells Point the Way to Specific Immunotherapy for Autoimmune Disease
Cardiovascular & Hematological Disorders-Drug Targets Clinical Pharmacogenetics of Methotrexate
Current Drug Metabolism Synthesis and Biological Activities of Substituted Benzoxazepine: A Review
Mini-Reviews in Organic Chemistry Potential Interactions between miRNAs and Hypoxia: A New Layer in Cancer Hypoxia
Anti-Cancer Agents in Medicinal Chemistry uPAR as Anti-Cancer Target: Evaluation of Biomarker Potential, Histological Localization, and Antibody-Based Therapy
Current Drug Targets